We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

228 hedge funds and large institutions have $2.31B invested in Celldex Therapeutics in 2026 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 67 increasing their positions, 58 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

329% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 14

50% more funds holding in top 10

Funds holding in top 10: 6 → 9 (+3)

23% more funds holding

Funds holding: 185 → 228 (+43)

16% more capital invested

Capital invested by funds: $2B → $2.31B (+$314M)

16% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 58

1.19% less ownership

Funds ownership: 110.21% → 109.01% (-1.2%)

38% less call options, than puts

Call options by funds: $3.79M | Put options by funds: $6.1M

Holders
228
Holders Change
+43
Holders Change %
+23.24%
% of All Funds
2.81%
Holding in Top 10
9
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+50%
% of All Funds
0.11%
New
60
Increased
67
Reduced
58
Closed
14
Calls
$3.79M
Puts
$6.1M
Net Calls
-$2.31M
Net Calls Change
-$3.85M

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$40.1M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.1M
3
IC
Ikarian Capital
Texas
+$12.6M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$11.1M
5
EP
Eversept Partners
New York
+$9.63M

Top Sellers

1
BG
Bellevue Group
Switzerland
-$65.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$31.6M
3
PCH
Polar Capital Holdings
United Kingdom
-$27.4M
4
DTC
Deep Track Capital
Connecticut
-$16.8M
5
EAM
Eventide Asset Management
Massachusetts
-$16.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$272M +$13.1M +480,868 +6%
KCM
2
Kynam Capital Management
New Jersey
$185M -$2.8M -102,613 -2%
BlackRock
3
BlackRock
New York
$170M -$2.23M -81,930 -2%
Fidelity Investments
4
Fidelity Investments
Massachusetts
$119M -$31.6M -1,158,421 -24%
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$102M +$40.1M +1,471,582 +84%
VCM
6
Vanguard Capital Management
Pennsylvania
$93.9M +$80.7M +2,960,895 New
State Street
7
State Street
Massachusetts
$88.9M -$16.2M -593,545 -17%
CC
8
Commodore Capital
New York
$85.5M +$3.59M +131,616 +5%
T. Rowe Price Associates
9
T. Rowe Price Associates
Maryland
$66.2M +$1.27M +46,627 +2%
EP
10
Eversept Partners
New York
$56.7M +$9.63M +353,291 +25%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$53.6M +$1.65M +60,545 +4%
B
12
Braidwell
Connecticut
$43M -$13.7M -502,027 -27%
DTC
13
Deep Track Capital
Connecticut
$40.7M -$16.8M -616,759 -32%
Millennium Management
14
Millennium Management
New York
$39.8M +$1.11M +40,827 +3%
VPC
15
Vestal Point Capital
New York
$38.8M +$1.61M +59,165 +5%
BG
16
Bellevue Group
Switzerland
$38.1M -$65.9M -2,417,669 -67%
NHAS
17
Novo Holdings A/S
Denmark
$38.1M – – –
Dimensional Fund Advisors
18
Dimensional Fund Advisors
Texas
$33.6M +$11.1M +407,818 +63%
EAM
19
Eventide Asset Management
Massachusetts
$32.9M -$16.5M -605,559 -37%
Fisher Asset Management
20
Fisher Asset Management
Washington
$32.2M +$2.09M +76,490 +8%
Goldman Sachs
21
Goldman Sachs
New York
$31.4M -$2.17M -79,715 -7%
Pictet Asset Management
22
Pictet Asset Management
Switzerland
$29.3M -$1.22M -44,920 -5%
EC
23
Elmind Capital
New York
$27.4M – – –
American Century Companies
24
American Century Companies
Missouri
$27.2M +$29.6K +1,084 +0.1%
Bank of America
25
Bank of America
North Carolina
$22.5M +$8.01M +293,759 +71%
1
2 3 4 5

CLDX Hedge Fund Activity: Q1 2026 in Review

228 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2026, worth a combined $2.31B — up 16% from $2B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new CLDX positions and 14 closed out — a net gain of 46 holders — while 67 added to existing stakes and 58 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $40.1M. The largest seller was Bellevue Group, cutting an estimated $65.9M.

  • 228 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2026, up from 185 in Q4 2025.
  • Funds reported $2.31B of Celldex Therapeutics stock for Q1 2026, up 16% quarter-over-quarter.
  • 60 funds opened new Celldex Therapeutics positions in Q1 2026 and 14 closed out, a net change of +46 holders.
  • The largest Celldex Therapeutics buyer in Q1 2026 was Point72 Asset Management, an estimated $40.1M added.
  • The largest Celldex Therapeutics seller in Q1 2026 was Bellevue Group, an estimated $65.9M sold.

Based on aggregated 13F filings for Q1 2026.